A Plasma biomarker panel of four MicroRNAs for the diagnosis of prostate cancer

Australian Prostate Cancer BioResource, Farhana Matin, Varinder Jeet, Leire Moya, Luke A. Selth, Suzanne Chambers, Judith A. Clements, Jyotsna Batra

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Prostate cancer is diagnosed in over 1 million men every year globally, yet current diagnostic modalities are inadequate for identification of significant cancer and more reliable early diagnostic biomarkers are necessary for improved clinical management of prostate cancer patients. MicroRNAs (miRNAs) modulate important cellular processes/pathways contributing to cancer and are stably present in body fluids. In this study we profiled 372 cancer-associated miRNAs in plasma collected before (∼60% patients) and after/during commencement of treatment (∼40% patients), from age-matched prostate cancer patients and healthy controls, and observed elevated levels of 4 miRNAs - miR-4289, miR-326, miR-152-3p and miR-98-5p, which were validated in an independent cohort. The miRNA panel was able to differentiate between prostate cancer patients and controls (AUC = 0.88). Analysis of published miRNA transcriptomic data from clinical samples demonstrated low expression of miR-152-3p in tumour compared to adjacent non-malignant tissues. Overexpression of miR-152-3p increased proliferation and migration of prostate cancer cells, suggesting a role for this miRNA in prostate cancer pathogenesis, a concept that was supported by pathway analysis of predicted miR-152-3p target genes. In summary, a four miRNA panel, including miR-152-3p which likely targets genes with key roles in prostate cancer pathogenesis, has the potential to improve early prostate cancer diagnosis.

LanguageEnglish
Article number6653
Number of pages15
JournalScientific Reports
Volume8
DOIs
Publication statusPublished - 27 Apr 2018
Externally publishedYes

Bibliographical note

Copyright The Author(s) 2018. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Cite this

Australian Prostate Cancer BioResource, Matin, F., Jeet, V., Moya, L., Selth, L. A., Chambers, S., ... Batra, J. (2018). A Plasma biomarker panel of four MicroRNAs for the diagnosis of prostate cancer. Scientific Reports, 8, [6653]. https://doi.org/10.1038/s41598-018-24424-w
Australian Prostate Cancer BioResource ; Matin, Farhana ; Jeet, Varinder ; Moya, Leire ; Selth, Luke A. ; Chambers, Suzanne ; Clements, Judith A. ; Batra, Jyotsna. / A Plasma biomarker panel of four MicroRNAs for the diagnosis of prostate cancer. In: Scientific Reports. 2018 ; Vol. 8.
@article{718ce592bcc24774bf78f0b8bd7c5401,
title = "A Plasma biomarker panel of four MicroRNAs for the diagnosis of prostate cancer",
abstract = "Prostate cancer is diagnosed in over 1 million men every year globally, yet current diagnostic modalities are inadequate for identification of significant cancer and more reliable early diagnostic biomarkers are necessary for improved clinical management of prostate cancer patients. MicroRNAs (miRNAs) modulate important cellular processes/pathways contributing to cancer and are stably present in body fluids. In this study we profiled 372 cancer-associated miRNAs in plasma collected before (∼60{\%} patients) and after/during commencement of treatment (∼40{\%} patients), from age-matched prostate cancer patients and healthy controls, and observed elevated levels of 4 miRNAs - miR-4289, miR-326, miR-152-3p and miR-98-5p, which were validated in an independent cohort. The miRNA panel was able to differentiate between prostate cancer patients and controls (AUC = 0.88). Analysis of published miRNA transcriptomic data from clinical samples demonstrated low expression of miR-152-3p in tumour compared to adjacent non-malignant tissues. Overexpression of miR-152-3p increased proliferation and migration of prostate cancer cells, suggesting a role for this miRNA in prostate cancer pathogenesis, a concept that was supported by pathway analysis of predicted miR-152-3p target genes. In summary, a four miRNA panel, including miR-152-3p which likely targets genes with key roles in prostate cancer pathogenesis, has the potential to improve early prostate cancer diagnosis.",
author = "{Australian Prostate Cancer BioResource} and Farhana Matin and Varinder Jeet and Leire Moya and Selth, {Luke A.} and Suzanne Chambers and Clements, {Judith A.} and Jyotsna Batra",
note = "Copyright The Author(s) 2018. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",
year = "2018",
month = "4",
day = "27",
doi = "10.1038/s41598-018-24424-w",
language = "English",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Springer, Springer Nature",

}

Australian Prostate Cancer BioResource, Matin, F, Jeet, V, Moya, L, Selth, LA, Chambers, S, Clements, JA & Batra, J 2018, 'A Plasma biomarker panel of four MicroRNAs for the diagnosis of prostate cancer', Scientific Reports, vol. 8, 6653. https://doi.org/10.1038/s41598-018-24424-w

A Plasma biomarker panel of four MicroRNAs for the diagnosis of prostate cancer. / Australian Prostate Cancer BioResource; Matin, Farhana; Jeet, Varinder; Moya, Leire; Selth, Luke A.; Chambers, Suzanne; Clements, Judith A.; Batra, Jyotsna.

In: Scientific Reports, Vol. 8, 6653, 27.04.2018.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - A Plasma biomarker panel of four MicroRNAs for the diagnosis of prostate cancer

AU - Australian Prostate Cancer BioResource

AU - Matin, Farhana

AU - Jeet, Varinder

AU - Moya, Leire

AU - Selth, Luke A.

AU - Chambers, Suzanne

AU - Clements, Judith A.

AU - Batra, Jyotsna

N1 - Copyright The Author(s) 2018. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2018/4/27

Y1 - 2018/4/27

N2 - Prostate cancer is diagnosed in over 1 million men every year globally, yet current diagnostic modalities are inadequate for identification of significant cancer and more reliable early diagnostic biomarkers are necessary for improved clinical management of prostate cancer patients. MicroRNAs (miRNAs) modulate important cellular processes/pathways contributing to cancer and are stably present in body fluids. In this study we profiled 372 cancer-associated miRNAs in plasma collected before (∼60% patients) and after/during commencement of treatment (∼40% patients), from age-matched prostate cancer patients and healthy controls, and observed elevated levels of 4 miRNAs - miR-4289, miR-326, miR-152-3p and miR-98-5p, which were validated in an independent cohort. The miRNA panel was able to differentiate between prostate cancer patients and controls (AUC = 0.88). Analysis of published miRNA transcriptomic data from clinical samples demonstrated low expression of miR-152-3p in tumour compared to adjacent non-malignant tissues. Overexpression of miR-152-3p increased proliferation and migration of prostate cancer cells, suggesting a role for this miRNA in prostate cancer pathogenesis, a concept that was supported by pathway analysis of predicted miR-152-3p target genes. In summary, a four miRNA panel, including miR-152-3p which likely targets genes with key roles in prostate cancer pathogenesis, has the potential to improve early prostate cancer diagnosis.

AB - Prostate cancer is diagnosed in over 1 million men every year globally, yet current diagnostic modalities are inadequate for identification of significant cancer and more reliable early diagnostic biomarkers are necessary for improved clinical management of prostate cancer patients. MicroRNAs (miRNAs) modulate important cellular processes/pathways contributing to cancer and are stably present in body fluids. In this study we profiled 372 cancer-associated miRNAs in plasma collected before (∼60% patients) and after/during commencement of treatment (∼40% patients), from age-matched prostate cancer patients and healthy controls, and observed elevated levels of 4 miRNAs - miR-4289, miR-326, miR-152-3p and miR-98-5p, which were validated in an independent cohort. The miRNA panel was able to differentiate between prostate cancer patients and controls (AUC = 0.88). Analysis of published miRNA transcriptomic data from clinical samples demonstrated low expression of miR-152-3p in tumour compared to adjacent non-malignant tissues. Overexpression of miR-152-3p increased proliferation and migration of prostate cancer cells, suggesting a role for this miRNA in prostate cancer pathogenesis, a concept that was supported by pathway analysis of predicted miR-152-3p target genes. In summary, a four miRNA panel, including miR-152-3p which likely targets genes with key roles in prostate cancer pathogenesis, has the potential to improve early prostate cancer diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=85046118750&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-24424-w

DO - 10.1038/s41598-018-24424-w

M3 - Article

VL - 8

JO - Scientific Reports

T2 - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 6653

ER -

Australian Prostate Cancer BioResource, Matin F, Jeet V, Moya L, Selth LA, Chambers S et al. A Plasma biomarker panel of four MicroRNAs for the diagnosis of prostate cancer. Scientific Reports. 2018 Apr 27;8. 6653. https://doi.org/10.1038/s41598-018-24424-w